Advertisement

Indian Journal of Gastroenterology

, Volume 33, Issue 4, pp 301–307 | Cite as

Fecal microbiota transplantation for management of Clostridium difficile infection

  • Chetana Vaishnavi
Review Article

Abstract

The widespread use of antibiotics has led Clostridium difficile infection (CDI) to become a common problem with pronounced medical and economic effects. The recurrence of CDI after treatment with standard antibiotics is becoming more common with the emergence of more resistant strains of C. difficile. As CDI is an antibiotic-associated disease, further treatment with antibiotic is best avoided. As the gut flora is severely disturbed in CDI, approaches that restore the gut microbiota may become good alternative modes of CDI therapies. Fecal microbiota transplantation (FMT) is the procedure of transplantation of fecal bacteria from a healthy donor individual into a patient for restoration of the normal colonic flora. Thus, FMT helps in the eradication of C. difficile and resolution of clinical symptoms such as diarrhea, cramping, and urgency. Though this approach to treatment is not new, presently, it has become an alternative and promising way of combating infections. The procedure is not in regular use because of the time required to identify a suitable donor, the risk of introducing opportunistic pathogens, and a general patient aversion to the transplant. However, FMT is gaining popularity because of its success rate as a panacea for recurrent attacks of CDI and is being increasingly used in clinical practice. This review describes the rationale, the indications, the results, the techniques, the potential donors, the benefits as well as the complications of fecal microbiota instillation to CDI patients in order to restore the normal gut flora.

Keywords

Donors Dysbiosis Methods Rationale 

Notes

Conflict of interest

CV does not have any conflict of interest to declare.

References

  1. 1.
    Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009;15:285–9.Google Scholar
  2. 2.
    van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill. 2009;14. pii:19316.Google Scholar
  3. 3.
    Kelly CP. Fecal microbiota transplantation—an old therapy comes of age. N Engl J Med. 2013;368:474–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Sanders WE, Sanders C. Modification of normal flora by antibiotics: Effects on individuals and the environment. In: Root RK, Sande MA, (eds). New Dimensions in Antimicrobial Therapy: Contemporary Issues in Infectious Diseases. New York: Churchill Livingstone; 1984. pp. 217–41.Google Scholar
  5. 5.
    Grehan MJ, Borody TJ, Leis SM, et al. Durable alternation of the colonic microbiota by administration of donor fecal flora. J Clin Gastroenterol. 2010;44:551–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80:62–73.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67:742–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lawley TD, Clare S, Deakin LJ, et al. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol. 2010;76:6895–900.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Deakin LJ, Clare S, Fagan RP, et al. Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun. 2012;80:2704–11.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lawley TD, Clare S, Walker AW, et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun. 2009;77:3661–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol. 2012;5:403–20.CrossRefGoogle Scholar
  12. 12.
    Smits LP, Bouter KEC, De Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9:88–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Rembacken BJ, Snelling M, Hawkey PM, Chalmers DM, Axon A. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Lanzini A, Lanzaroto F, Villanacci V, et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther. 2009;29:1299–308.PubMedCrossRefGoogle Scholar
  16. 16.
    Brandt L, Aroniadis O, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Ananthaswamy A. Faecal transplant eases symptoms of Parkinson’s. New Sci. 2011;209:8–9.Google Scholar
  18. 18.
    Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38:475–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044–9.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–9.PubMedGoogle Scholar
  21. 21.
    Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am Surg. 1981;47:178–83.PubMedGoogle Scholar
  22. 22.
    Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283–5.PubMedGoogle Scholar
  25. 25.
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580–5.PubMedCrossRefGoogle Scholar
  26. 26.
    McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Chang JY, Antopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44:354–60.PubMedGoogle Scholar
  29. 29.
    You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Yoon S, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease (CDI) by donated stool transplanted via colonoscopy: a case series of twelve patients. J Clin Gastroenterol. 2010;44:562–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Rohlke F, Surawicz CM, Stollman NH. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol. 2010;44:567–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Kaur S, Vaishnavi C, Ray R, Kochhar R, Prasad KK. Effect of biotherapeutics on cyclosporine-induced Clostridium difficile infection in mice. J Gastroenterol Hepatol. 2010;25:1–7.CrossRefGoogle Scholar
  33. 33.
    Borody T, Wettstein A, Leis S, Hills L, Campbell J, Torres M. Clostridium difficile complicating inflammatory bowel diseases: pre- and post-treatment findings. Gastroenterology. 2008;134 4 Suppl 1:A–361.Google Scholar
  34. 34.
    Anderson JL, Edney RJ, Whelan K. Systematic review: fecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503–16.PubMedCrossRefGoogle Scholar
  35. 35.
    Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.PubMedCrossRefGoogle Scholar
  36. 36.
    Russell G, Kaplan J, Ferraro M, Michelow I. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics. 2010;126:e239–42.Google Scholar
  37. 37.
    van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.PubMedCrossRefGoogle Scholar
  38. 38.
    Lund-Tonnesen S, Berstad A, Schreiner A, et al. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen. 1998;118:1027–30.PubMedGoogle Scholar
  39. 39.
    Hamilton M, Weingarden A, Sadowsky M, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Wettstein A, Borody T, Leis S, Chongan J, Torres M, Hills L. Faecal bacteriotherapy—an effective treatment for relapsing symptomatic Clostridium difficile infection. Abstract WED-G-67. In: 15th Gut. United European Gastroenterology Week. United European Gastroenterology Federation, France, 2007:39 Suppl 1.Google Scholar
  41. 41.
    Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010;8:471–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Kassam Z, Hundal R, Marshall J, Lee C. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012;172:191–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Paterson D, Iredell J, Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhoea. Med J Aust. 1994;160:232–3.PubMedGoogle Scholar
  44. 44.
    Louie T. Home-based fecal flora infusion to arrest multiply-recurrent Clostridium difficile infection (CDI). In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC) Arlington, VA: Infectious Disease Society of America, 2008.Google Scholar
  45. 45.
    MacConnachie A, Fox R, Kennedy D, Seaton R. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM. 2009;102:781–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Rubin T, Gessert C, Aas J. Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc. 2009;57:2386.PubMedCrossRefGoogle Scholar
  47. 47.
    Duplessis C, You D, Johnson M, Speziale A. Efficacious outcome employing fecal bacteriotherapy in severe Crohn’s colitis complicated by refractory Clostridium difficile infection. Infection. 2012;40:469–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Nieuwdorp M, van Nood E, van Speelman P, et al. Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces. Ned Tijdschr Geneeskd. 2008;152:1927–32.PubMedGoogle Scholar
  49. 49.
    Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010;42:857–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Gustafsson A, Berstad A, Lund-Tonnesen S, Midtvedt T, Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol. 1999;34:580–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Kelly C, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Ho N, Prasad V. Clostridium difficile diarrhea and fecal transplantation. J Clin Gastroenterol. 2011;45:742–3.PubMedCrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2014

Authors and Affiliations

  1. 1.Department of GastroenterologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations